Isorhamnetin exhibits a multifaceted therapeutic impact on diabetes, encompassing anti-diabetic effects through insulin pathway regulation, modulation of carbohydrate metabolism, inhibition of NF-κB activation for vascular protection, and potential therapeutic benefits for diabetic neuropathy by alleviating neuropathic pain and improving nerve conduction velocity in rat models (47). Here, NFKB1 is linked to diabetes mellitus.